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Abstract
Background: Plasma microRNA (miRNA) has become a promising biomarker for detecting cancer; however, it
remains uncertain whether miRNA expression levels in plasma reflect those in tumor cells. Our aim was to
determine the biological relevance of miR-92a, which has been implicated as an oncomiR in both plasma and
leukemia cells in patients with acute leukemia and to evaluate whether it could be a novel biomarker for
monitoring these patients.
Results: We quantified the expression level of miR-92a in both cells and plasma by reverse transcription
polymerase chain reaction in 91 patients with acute leukemia. We also determined miR-92a expression levels in
peripheral blood mononuclear cells (PBMNC) from normal controls. We compared miR-92a expression in plasma
with its expression in leukemia cells. Synthetic anti-miR-92a inhibitor was transfected into Raji and OM9;22 cells,
and apoptosis was assessed. For in vivo assessment, 6-week-old female nude mice were injected with U937 cells,
and miR-92a expression in plasma and tumors was measured. The level of miR-92a expression in fresh leukemia
cells was highly variable compared with PBMNC, but significantly lower compared with CD34-positive cells
obtained from healthy volunteers. We also noticed that miR-92a was preferentially expressed in acute
lymphoblastic leukemia (ALL) cells in comparison with acute myeloid leukemia (AML) cells. More specifically,
cellular miR-92a expression was significantly increased in a subset of ALL cells, and ALL patients with overexpressed
miR-92a had poor prognoses. The anti-miR-92a inhibitor-treated Raji and OM9;22 cells revealed an increase of
apoptotic cells. Notably, the cell to plasma ratio of miR-92a expression was significantly higher in both AML and
ALL cells compared with PBMNC from healthy volunteers. In tumor-bearing mice, the plasma miR-92a level was
significantly decreased in accordance with tumor growth, while tumor tissue was strongly positive for miR-92a.
Conclusions: The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients. The inverse
correlation of miR-92a expression between cells and plasma and the cell to plasma ratio may be important to
understanding the clinical and biological relevance of miR-92a in acute leukemia.
Background
MicroRNAs (miRNAs) are a class of small noncoding
RNAs of 19 to 25 nucleotides in size that are endogen-
ously expressed in mammalian cells [1-3]. They regulate
gene expression by repressing mRNA translation or
cleaving target mRNA. As a new family of gene regula-
tors, miRNAs are involved in the modulation of multiple
cellular pathways, including cell proliferation, differentia-
tion, and apoptosis. Recent evidence indicates that miR-
NAs can function as tumor suppressors and oncogenes,
and they are therefore referred to as “oncomiRs” [4].
Evidence suggests that certain tumor-derived circulat-
ing miRNAs, such as miR-155, miR-21, miR-15b, miR-
16, and miR-24, are detected in cell-free specimens,
such as plasma and serum of cancer patients, regardless
of the high RNAse activity in plasma; therefore, this
may reflect tumor-derived miRNA [5,6]. In general, the
level of miRNA in cell-free specimens is consistent with
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identified miR-92a as a plasma biomarker in human leu-
kemia [8]. We found that the miR-92a plasma expres-
sion level was significantly lower–approximately only 1/
100th–in both acute myeloid leukemia (AML) and acute
lymphoblastic leukemia (ALL) compared with normal
controls. Since overexpression of the miR-17-92 cluster
has been demonstrated in various neoplasias, including
lymphoma and lung cancer [9-13], miR-92a is categor-
ized as a possible oncomiR. The question has thus
arisen regarding why the level of miR-92a is down-regu-
lated in acute leukemia cells.
We therefore set out to determine miR-92a expression
levels in acute leukemia cell lines and fresh acute leuke-
mia cells. We used peripheral blood mononuclear cells
(PBMNC) obtained from healthy volunteers as controls.
We found high miR-92a expression in leukemia cell
lines as well as in CD34-positive cells obtained from
healthy volunteers. Although miR-92a expression in
fresh leukemia cells was highly variable, miR-92a expres-
sion was significantly increased in a subset of ALL cells,
and ALL patients with overexpressed miR-92a had poor
outcomes. We then reanalyzed previously published
data on plasma miR-92a expression [8] with respect to
the expression in leukemia cells. We now show that the
cell to plasma ratio of miR-92a expression is signifi-
cantly higher for both AML and ALL compared with
the ratio based on PBMNC from healthy volunteers. We
also show that the regulation of miRNA is generally
impaired in acute leukemia. Our results shed light on
cell-free miRNA dynamics in cancer patients.
Methods
Patients and cells
In the current study, 91 patients aged 17-72 years with
untreated, primary acute leukemia whose leukemia cells
were more than 80% were included: 45 patients had
ALL with pre-B phenotype and 46 had AML. CD34-
positive cells from five healthy volunteers and PBMNC
from 20 healthy volunteers were used as controls for
cellular miR-92a expression. A study using plasma speci-
mens was reported elsewhere [8]. This study was
approved by the institutional review board of Tokyo
Medical University. Written informed consent according
to the Declaration of Helsinki was obtained from all
patients prior to collection of the specimens. All 91
patients were treated according to the Japan Adult Leu-
kemia Study Group protocols in the same institution.
Human myeloid leukemia cell lines (HL-60, Kasumi-1,
KOPM-K, U937, and K562), human lymphoid leukemia
c e l ll i n e s( B A L L - 2 ,O M 9 ; 2 2 ,H A L - 0 1 ,N A L M 2 1 ,
NALM24), and a human Burkitt lymphoma cell line
(Raji) were also used in a part of this study.
Quantitative reverse transcription polymerase chain
reaction of mature miRNAs
CD34-positive cells of healthy volunteers were isolated
using an Indirect CD34 MicroBead Kit and Magnetic
Cell Sorting system (Miltenyi Biotec, Auburn, California),
according to the manufacturer’s instructions. Total RNA
in cells was isolated using an miRNeasy Mini Kit (Qiagen,
Germantown, Maryland), and RNA in plasma was
extracted as reported previously [8]. MicroRNAs were
quantified using TaqMan MicroRNA assays (Applied
Biosystems, Foster City, California) with modifications.
The microRNA specific stem-loop primers hsa-miR-92a
(000431; Applied Biosystems), RNU6B (001093; Applied
Biosystems), and hsa-miR-638 (Applied Biosystems) were
used in the study. The expression of miR-92a was calcu-
lated using 2- ΔΔC
t methods, and mean cycle threshold
(C
t)v a l u e sf o ra l lm i R N A sw e r eq u a n t i f i e du s i n g
sequence detection system software (SDS, version 1.02;
Applied Biosystems). We used total RNA obtained from
either plasma or PBMNC of healthy volunteers as con-
trols, and the miR-92a expression levels in acute leuke-
mia specimens were expressed as “ratios to controls”.
Antisense oligonucleotides and apoptosis assay
Antisense oligonucleotides and their respective
scrambled control oligonucleotides were purchased from
Applied Biosystems: an anti-miR-92a inhibitor
(AM10916) and anti-miR negative control #1
(AM17011). To assess their effects, cells were plated to a
density of 1 × 10
5 cells/well in 24-well dishes and then
transfected with the oligonucleotides (50 nM) using a
SuperFect Transfection Reagent (Qiagen) (day 1). The
cells were then transfected again with oligonucleotides
(50 nM) on day 5 and analyzed. The annexin V-binding
capacities of the treated cells were examined using the
annexin V-biotin apoptosis detection kit (Calbiochem, La
Jolla, California), using an Agilent 2100 Bioanalyzer (Agi-
lent, Wilmington, Delaware), as previously reported [14].
The miR-92a expression in plasma and cells from tumor-
bearing mice
For the in vivo assessment of miR-92a, 6-week-old
female nude mice were injected with U937 cells. The
miR-92a expression in plasma and tumor was measured
on day 7 and day 18. Tumors were collected at the pre-
determined times and fixed in paraformaldehyde.
Paraffin-embedded tissues were sectioned and pro-
cessed for gross histopathology by hematoxylin-eosin
staining. Locked nucleic acid (LNA)-modified probes for
miR-92a and negative control (miRCURY-LNA detec-
tion probe; Exiqon, Vedbaek, Denmark) were used to
detect miR-92a expression in spleen and tumor, as
reported previously [8].
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We used GraphPad Prism 5.0 software (GraphPad Soft-
ware Inc., San Diego, California) for statistical analysis.
A Mann-Whitney test was used to determine statistical
significances between the control and test groups. One-
way ANOVA was used to determine statistically signifi-
cant relationships among more than three groups.
P-values less than 0.05 were considered to indicate
statistically significant differences.
Results
The miR-92a expression levels in immortalized leukemia
cell lines and CD34-positive cells from healthy volunteers
We first examined miR-92a expression levels in leuke-
mia cell lines as well as CD34-positive cells obtained
from healthy volunteers (Figure 1A). Cellular miR-92a
expression was expressed as ratios based on the aver-
age from normal PBMNC controls (ratios to controls
in the Figure 1A), and we found miR-92a expression to
be 5- to 10-fold higher in CD34-positive cells. Total
RNA was extracted from a serum-free culture of cell
lines to exclude contamination from bovine miRNA.
Most of the immortalized cell lines showed more than
10-fold higher miR-92a expression compared with con-
trols. In the five myeloid leukemia cell lines, miR-92a
expression ranged from 10.2 to 25 (mean ± SD, 15.1 ±
6.665) and was significantly higher than in CD34-posi-
tive cells (mean ± SD, 7.814 ± 2.360; P = 0.0251).
Similarly, in ALL cell lines, miR-92a expression ranged
from 9.361 to 22.19 (mean ± SD, 12.52 ± 5.433)
and tended to be higher than in CD34-positive cells
(P = 0.0538).
 
 
Figure 1 MiR-92a expression in leukemia cells and in CD34-positive cells obtained from healthy volunteers. A: Cellular miR-92a
expression levels in CD34-positive cells obtained from normal individuals, AML cell lines, and ALL cell lines. C: Controls (PBMNC obtained from
healthy volunteers.) B: MiR-92a expression in AML cells and control cells. C: MiR-92a expression in ALL cells and control cells. D: Comparison of
miR-92a expression in acute leukemia cells as well as CD34-positive cells and PBMNC obtained from healthy volunteers.
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be linked to constant cell growth such as in immorta-
lized leukemia cell lines and hemopoietic stem cells. In
keeping with our previous observation using in situ
hybridization of miR-92a in AML cells [8], leukemia
cells possessed high levels of miR-92a expression.
MiR-92a expression in fresh leukemia cells
Unlike leukemia cell lines, the miR-92a expression levels
in fresh leukemia cells were generally low. In addition,
these expression levels were highly variable compared
with controls (mean ± SD, 1.257 ± 0.2261).
We found wide variation of miR-92a expression in
fresh AML cells (Figure 1B): miR-92a expression ranged
from 0.1199 to 4.724 (mean ± SD, 1.131 ± 1.112), and
there was no significant difference in miR-92a expres-
sion between AML cells and PBMNC; however, miR-
92a expression varied among FAB subtypes. The miR-
92a expression in AML-M3 was significantly lower than
in AML-M1 (P = 0.0325) (Additional file 1), indicating
that miR-92a expression may be linked to cellular differ-
entiation in AML cells.
Similar to expression in AML cells, miR-92a expres-
sion in ALL cells varied from 0.2109 to 9.987 (mean ±
SD, 1.257 ± 0.2261) (Figure 1C) and was significantly
lower than in CD34-positive control cells (P = 0.0014)
(Figure 1D). There was no significant difference in miR-
92a expression levels among cytogenetic ALL groups
(Additional file 2).
In contrast to expression in AML cells, miR-92 expres-
sion in ALL cells was higher than in PBMNC (P =
0.0272), and miR-92a expression was significantly higher
in ALL cells than in AML cells (P = 0.0021) (Figure 1D).
Potential role of miR-92a in ALL cells
On the basis of the results obtained from cellular miR-
9 2 ae x p r e s s i o n ,m i R - 9 2 aa p p e a r st op l a ys o m er o l ei n
ALL cells but not AML cells. We arbitrarily divided
ALL patients into two groups; group 1 was composed of
ALL patients whose miR-92a expression levels were
greater than three times the average level of normal
PBMNC controls (n = 9), and the remaining ALL
patients, whose miR-92a expression levels were lower
than threefold normal PBMNC controls, were assigned
to group 2 (n = 34). Patients in group 1 had significantly
shorter survival compared with those in group 2 (P =
0.0186) (Figure 2A). This suggests that cellular miR-92a
levels may be linked to poor outcome in ALL patients.
To further elucidate the potential role of miR-92a in
ALL cells, we used antisense oligonucleotides to exam-
ine the effects of reducing miR-92a expression in Raji
and OM9;22 cells. Although the anti-miR-92a inhibitor
did not inhibit growth in the cell lines (data not shown),
we found an increase in annexin-positive cells in the
anti-miR-92a inhibitor-treated Raji and OM9;22 cells
compared with the anti-miR negative control-treated
cells (Figure 2B). These findings suggest that miR-92a
may act as oncomiRs in fresh ALL cells.
Cell to plasma ratio of miR-92a expression is elevated in
acute leukemia
We then reanalyzed previously published data on
plasma miR-92a expression [8] with respect to its
expression in leukemia cells. Since we could not detect
U6B, which is commonly used as a internal standard for
miRNA expression analysis in cells, we used miR-638 as
a reference in each sample, as previously reported [8].
We could not find any obvious correlation between
plasma miR-92a and cellular miR-92a in any case since
plasma miR-92a levels were extremely low in most of
t h es a m p l e s( F i g u r e3 A ) .E v e n t u a l l y ,w ef o u n dt h a tt h e
cell to plasma ratio of miR-92a was significantly higher
in both AML (P = 0.016) and ALL (P < 0.0001) cells
compared with those in peripheral blood specimens
obtained from healthy individuals (Figure 3B). Receiver
operation characteristic (ROC) curve analysis clearly
s h o w sa na r e au n d e rt h eR O Cc u r v e( A U C )v a l u eo f
0.9959 (Figure 3C). This may indicate that release or
reuptake of miRNA by acute leukemia cells is different
from that of peripheral blood cells obtained from
healthy individuals.
To further elucidate the mechanism of release and
reuptake of miR-92a by leukemia cells, we measured
m i R - 9 2 ae x p r e s s i o ni nb o t hc e l l sa n ds u p e r n a t a n ti n
vitro. Cells (5 × 10
5 cells/ml) were cultured in a serum-
free medium for 24 hours, and miR-92a expression in
both cells and supernatant was analyzed. We found var-
ious levels of miR-92a expression in the supernatant
(Figure 3D). It is likely that the in vitro dynamics of
miR-92a are not reflected in living cells.
Low plasma miR-92a expression in tumor-bearing mice
To determine the expression levels of miR-92a in xeno-
transplanted tumor tissues, we performed in situ hybri-
dization using LNA-modified probes labeled with
digoxigenin. We found that miR-92a was strongly
expressed in tumors, while tumor tissue was negative
for the scramble probe (negative controls) (Figure 4A).
Although we could not rule out the possibility that
mouse miR-92a affects the level of miR-92a in mice
plasma, plasma miR-92a levels were significantly
decreased in accordance with tumor growth (P =
0.0142)(Figure 4B).
Discussion
This is the first report to circumstantiate the dysregulation
of miRNA in patients with acute leukemia by analyzing
miR-92a expression in both cells and plasma. First,
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and the expression pattern may be linked to clinical beha-
vior in ALL patients. Second, the cell to plasma ratio was
low in both AML and ALL, indicating the possibility that
leukemia cells retain miR-92a.
In AML, several studies have described the association
between cellular miRNA expression and chromosomal
abnormalities [15-17]. For example, up-regulation of miR-
127/125b/154/323/368/370/381 is associated with leuke-
mia cells with t(15;17), and up-regulation of miR-126* is
associated with those with t(8;21). It is likely that certain
chromosomal abnormalities or genetic changes, such as
FLT3-ITD and NPM1 mutations, may be more important
in defining the biological properties of AML cells. Indeed,
we could not determine the clinical relevance of miR-92a
when analyzing only a cell fraction of AML.
In contrast, we found cellular miR-92a appears to play
some role in a subset of ALL patients. This result was
not surprising since the miR-17-92 cluster is known to
be related to lymphoid development as well as lympho-
magenesis [13]. However, our results highlight the biolo-
gical and clinical properties of miR-92a in ALL cells in
that patients with higher expression of miR-92a had sig-
nificantly shorter survival. Although the knock-down of
miR-92a did not show growth inhibition, an increase in
apoptotic cells may indicate that miR-92a possibly inhi-
bits apoptosis in a subset of ALL cells. Recent reports
by Kotani et al. [18] demonstrated that the expression
of two tumor-suppressive miRNAs, miR-128b and miR-
221, was down-regulated in MLL-rearranged ALL
relative to other types of ALL and was related to gluco-
corticoid resistance. Zhang et al. [19] also reported that
miR-34a, miR-128a, miR-128b, and miR-146a are asso-
ciated with prednisolone response in pediatric ALL.
Kaddar et al. [7] have shown that miR-16 acts as an onco-
miR in childhood ALL and is thereby related to poor out-
come. In accordance with the current study, there may be
several prognostic parameter-associated miRNAs in ALL,
Figure 2 Role of miR-92a expression in ALL cells. A: ALL-group 1; miR-92a expression level is three times greater than that of normal controls
(n = 9). ALL-group 2; miR-92a expression level is a third or less than normal controls (n = 34). Patients of ALL-group 1 had significantly shorter
survival than ALL-group 2 patients (P = 0.0186). B: The left panel shows the efficacy of anti-sense oligonucleotides. MiR-92a expression level was
decreased only when cells were treated with anti-miR-92a inhibitor. The right panel shows the anti-apoptotic effect of miR-92a in Raji and
OM9;22 cells. Annexin-positive cells were more frequent in anti-miR-92a inhibitor-treated Raji and OM9;22 cells than in anti-miR negative control-
treated cells.
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linked to which miRNA effects is still unclear.
Several lines of evidence suggest that miRNA in cells as
well as circulating tumor-derived miRNA (i.e., in saliva,
urine, and plasma) plays an important role in cancer
development and progression [5,6,20-23]. Unlike miRNA
in cancer cells, the biological relevance of circulating
tumor-derived miRNA has not been fully elucidated. In
general, the level of miRNA in cells is consistent with the
levels in cell-free specimens such as plasma [7]. For
example, Mitchell et al. [6] found that plasma miR-141 is
overexpressed in prostate cancer patients. Also, Lawrie et
al. [5] found that patients with diffuse large B-cell lym-
phomas had high serum levels of miR-21, which was
associated with increased relapse-free survival. More
recently, plasma miR-29a and miR-92a have been found
to be significantly overexpressed in colorectal cancers
compared with normal controls [21]. These findings sug-
gest that circulating oncomiR expression levels are gener-
ally high in cancer patients; thereby, the cell to plasma
ratio of miRNA might be constant.
In this study, the cell to plasma ratio is remarkably
elevated in acute leukemia cells compared with the ratio
based on PBMNC obtained from healthy volunteers.
Our results showed a discrepancy between oncomiR
expression in cells and plasma. Park et al. [24] demon-
strated that miR-200a, which is commonly overex-
pressed in oral squamous cell carcinoma cell lines, was
present in significantly lower levels in the saliva of
patients with oral squamous cell carcinoma than in the
saliva of control subjects [23]. The most plausible expla-
nation for this discrepancy is that cancer-specific miR-
NAs undergo a more rapid degradation and/or have a
shorter half-life during the cell death process, similar to

 
Figure 3 Implication of plasma miR-92a. A: Plasma miR-92a expression levels in acute leukemia patients and normal controls. B: Cell to plasma
ratio of miR-92a expression. C: ROC curve of cell to plasma ratio in acute leukemia. D: The miR-92a expression in cells and supernatant. Cells
were cultured under serum-free conditions for 24 hours, and then total RNA was extracted from both cells and supernatant. The expression
levels of miR-92a in the supernatant are shown in closed boxes, and those in cells are show in open boxes.
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possible that release of miR-92a is impaired in acute
leukemia cells. Zernecke et al. [26] demonstrated that
extracellular exosomal miRNAs were transferred into
other cells such as endothelial cells. More recently,
Kosaka et al. [27] also demonstrated secretary mechan-
isms and intercellular transfer of miRNA in living cells.
Taking the information as a whole, we could not rule
out the possibility that the miR-92a in plasma may
transfer to other cells in acute leukemia. For this reason,
t h ec e l lt op l a s m ar a t i om a yb ei m p o r t a n ti nu n d e r -
standing the biological relevance of miR-92a in acute
leukemia.
Conclusions
We have shown a possible role of miR-92a in ALL cells.
The quantification of miR-92a in leukemia cells and
plasma may be used for monitoring leukemia in both
ALL and AML patients. Although questions still remain
about the underlying mechanism of miR-92a dynamics
in patients with acute leukemia, our results highlight the
impact of the cell to plasma ratio of miR-92a in patients
with acute leukemia. Obviously, the signal network
mediated by miR-92a needs to be clarified. Our results
anticipate a possible role of circulating miRNA in cancer
patients.
Additional material
Additional file 1: MiR-92a expression levels and FAB subtypes in
AML. MiR-92a expression levels in M1 were significantly higher than
those in M2 (P = 0.0033) and M3 (P = 0.0325).
Additional file 2: There was no significant difference in miR-92a
expression levels among ALL cytogenetic groups.
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